Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients

Approximately 45% of metastatic colorectal cancer (mCRC) patients with wild-type KRAS exon 2 are resistant to cetuximab treatment. We set out to identify additional genetic markers that might predict the response to cetuximab treatment. Fifty-three wild-type KRAS exon 2 mCRC patients were treated wi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Hsu, Hung-Chih, Thiam, Tan Kien, Lu, Yen-Jung, Yeh, Chien Yuh, Tsai, Wen-Sy, You, Jeng Fu, Hung, Hsin Yuan, Tsai, Chi-Neu, Hsu, An, Chen, Hua-Chien, Chen, Shu-Jen, Yang, Tsai-Sheng
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2016
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5008360/
https://ncbi.nlm.nih.gov/pubmed/26989027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8076
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg